Diseases We Target

We focus on areas of substantial unmet need

diseases we target

Committed to helping Fight Disease

Reata’s lead candidates, bardoxolone methyl and omaveloxolone, are being developed for the treatment of a variety of chronic and genetic diseases for which a substantial unmet need exists. Our pipeline of therapeutics is focused in two main pillars: chronic kidney disease (CKD) and neurology, with late stage programs in Alport syndrome, autosomal dominant polycystic kidney disease (ADPKD), and Friedreich's ataxia.